Literature DB >> 34251586

Hsa_circRNA_102541 regulates the development of atherosclerosis by targeting miR-296-5p/PLK1 pathway.

Na Du1, Mingjin Li2, Dan Yang3.   

Abstract

BACKGROUND: Cardiovascular disorders pose great threat to public health. As a common type of cardiovascular disease, atherosclerosis is characterized by high morbidity and mortality/recurrence rate. However, the pathogenesis of atherosclerosis is complex and not fully understood. The aim of this study was to investigate the influences of hsa_circRNA_102541 (circ_102541) on proliferation and apoptosis of HUVEC cells and to identify the underlying mechanisms.
METHODS: RT-PCR was used to determine the expression levels of circ_102541, miR-296-5p, and PLK1 in atherosclerosis and healthy blood samples. Following the transfection with sh-circ_102541, LV-circ_102541, miR-296-5p mimics, miR-296-5p inhibitors, and si-PLK1, cell proliferation was evaluated using CCK8 assay; cell apoptosis was determined by flow cytometry; dual luciferase assay was performed to examine the interaction between abovementioned molecules. The levels of associated markers including PCNA and caspase-3 were assessed by western blotting and RT-qPCR.
RESULTS: The expression of circRNA_102541 and PLK1 were significantly elevated in atherosclerosis specimens, where the level of miR-296-5p was reduced. Furthermore, circRNA_102541 could bind miR-296-5p and subsequently target PLK1. Following treatment with sh-circRNA_102541 or miR-296-5p mimics, proliferative ability and levels of PCNA were remarkably reduced in HUVEC cells, while apoptosis was significantly enhanced. Co-transfection with miR-296-5p mimics abrogated the effects induced by the overexpressed circ_102541. Additionally, treatment with si-PLK1 attenuated the biological behavior changes caused by miR-296-5p inhibitors in HUVEC cells. Moreover, transfection with LV-PLK1 reversed the effects triggered by miR-296-5p mimics.
CONCLUSION: Taken together, circRNA_102541 was upregulated in atherosclerosis, and knockdown of circRNA_102541 suppressed cell proliferation while promoted apoptosis of HUVEC cells via miR-296-5p/PLK1. This novel pathway may serve essential roles on the development of atherosclerosis, and circRNA_102541 could be a promising therapeutic candidate for the treatment of atherosclerosis.
© 2021. Royal Academy of Medicine in Ireland.

Entities:  

Keywords:  Apoptosis; Atherosclerosis; PLK1; Proliferation; hsa_circRNA_102541; miR-296-5p

Mesh:

Substances:

Year:  2021        PMID: 34251586     DOI: 10.1007/s11845-021-02708-x

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  3 in total

1.  CircRNA‑0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR‑107.

Authors:  Lin Shen; Yanyan Hu; Jianwei Lou; Sen Yin; Weiling Wang; Yuanyan Wang; Yong Xia; Wei Wu
Journal:  Mol Med Rep       Date:  2019-03-06       Impact factor: 2.952

2.  Physical activity, cardiorespiratory fitness and carotid intima thickness: sedentary occupation as risk factor for atherosclerosis and obesity.

Authors:  R Leischik; P Foshag; M Strauß; P Garg; B Dworrak; H Littwitz; J S Lazic; M Horlitz
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-09       Impact factor: 3.507

3.  Screening of up- and downregulation of circRNAs in HBV-related hepatocellular carcinoma by microarray.

Authors:  Shichang Cui; Zhiling Qian; Yuhan Chen; Lei Li; Peng Li; Huiguo Ding
Journal:  Oncol Lett       Date:  2017-10-25       Impact factor: 2.967

  3 in total
  2 in total

1.  Dynamic epigenetic age mosaicism in the human atherosclerotic artery.

Authors:  Silvio Zaina; Manel Esteller; Isabel Gonçalves; Gertrud Lund
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

Review 2.  Circular RNAs and Their Role in Exosomes.

Authors:  Zeping Han; Huafang Chen; Zhonghui Guo; Jian Shen; Wenfeng Luo; Fangmei Xie; Yu Wan; Shengbo Wang; Jianhao Li; Jinhua He
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.